Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

In Brief: TAP's Lupron Depot

  • News

Executive Summary

TAP's Lupron Depot: Leuprolide acetate for depot suspension approved Dec. 22 in a three-month 22.5 mg dosage form for the palliative treatment of advanced prostatic cancer. Lupron Depot was available previously for prostate cancer in a once-monthly 7.5 mg dose. TAP filed the NDA (20-517) for the three-month (84-day) formulation in December 1994. The company has committed to Phase IV studies of three-month Lupron Depot that include a one-year pharmacokinetic/pharmacodynamic study of multiple doses and a six-month study comparing once-monthly Lupron Depot to the three-month product with regard to stimulation of gonadotropin secretion upon reinjection...

Table

View full table

Tags:
Latest Headlines

US FDA’s Vaccine Office Emerges From Non-COVID-19 Backlog

AstraZeneca’s Farxiga Authorized Generic Aims To Broaden Access As Medicare Price Cut Looms

US FDA Adcomm Reform: Does Listening Session Suggest No Major Near-Term Changes?

It’s Official: FDA Drops Final Rule On LDTs

See All
UsernamePublicRestriction

Register

PS027455

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By